Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus paracasei N1115
- Development stage
- Unknown
- Lead developer
- Junlebao Dairy
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus paracasei N1115 is a specific probiotic strain developed by Junlebao Dairy in collaboration with Peking University. It is primarily utilized for its ability to modulate the gut microbiota, specifically by increasing the abundance of beneficial Firmicutes and decreasing opportunistic pathogens like Fusobacterium and Bilophila. Clinical research has focused on its potential to alleviate gastrointestinal symptoms (such as dyspepsia and constipation) in patients with end-stage kidney disease on peritoneal dialysis, as well as its impact on serum lipid profiles in individuals with dyslipidemia. The strain is thought to exert its effects through the production of short-chain fatty acids (SCFAs) and the restoration of intestinal microbial balance.
- Other names
- 副干酪乳杆菌N1115Lactobacillus paracasei strain N1115
Beyond the preview
Go deeper on lactobacillus paracasei N1115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus paracasei N1115.